Adult vaccinations against respiratory infections
Authors:
Open Access
- 31 January 2025
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 23 (2-4) , 135-147
Abstract
Lower respiratory infections have a huge impact on global health, especially in older individuals, immunocompromised people, and those with chronic comorbidities. The COVID-19 pandemic highlights the importance of vaccination. However, there are lower rates of vaccination in the adult population that are commonly due to a missed opportunity to vaccinate. Vaccination offers the best strategy to prevent hospitalization, complications, and death caused by lower respiratory infections. In this review, the authors provide an overview of the vaccines for lower respiratory infections in the adult population. The review highlights the available data about the impact of vaccines on preventing respiratory infections, focusing on the pneumococcal vaccine, influenza vaccine, COVID-19 vaccines, and respiratory syncytial virus (RSV) vaccines. The authors discuss the currently available scientific evidence on the role of vaccines against respiratory infections. Finally, the authors review the current recommendations for vaccines in the adult population. Scientific evidence on the effectiveness of vaccines against respiratory infections is important. An efficient implementation of adult immunization strategies will provide an opportunity to decrease the global burden of lower respiratory infections. Recognizing the existing vaccines and their recommendations for the adult population is essential to achieve a high vaccination rate in the population.Keywords
This publication has 92 references indexed in Scilit:
- Antibody Response to Respiratory Syncytial Virus Vaccination in Immunocompromised PersonsJAMA, 2025
- Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus InfectionJAMA Internal Medicine, 2024
- Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position PaperArchivos de Bronconeumología, 2024
- Up the Nose and Down the Windpipe May Be the Path to New and Improved COVID-19 VaccinesJAMA, 2024
- Comparison of Medical and Mental Health Sequelae Following Hospitalization for COVID-19, Influenza, and SepsisJAMA Internal Medicine, 2023
- Understanding the Global Burden of Influenza in Adults Aged 18–64 years: A Systematic Literature Review from 2012 to 2022Advances in Therapy, 2023
- High Clinical Burden of Influenza Disease in Adults Aged ≥ 65 Years: Can We Do Better? A Systematic Literature ReviewAdvances in Therapy, 2023
- Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018JAMA Network Open, 2022
- State-Level Variations and Factors Associated with Adult Vaccination Coverage: A Multilevel Modeling ApproachPharmacoEconomics - Open, 2021
- Increased incidence of co-infection in critically ill patients with influenzaIntensive Care Medicine, 2016